Tonix Pharmaceuticals Holding Corp.

SecurityTNXP / Tonix Pharmaceuticals Holding Corp.
InstitutionEquitable Holdings, Inc.
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Equitable Holdings, Inc. closes position in TNXP / Tonix Pharmaceuticals Holding Corp.

On November 14, 2025 - Equitable Holdings, Inc. filed a 13F-HR form disclosing ownership of 0 shares of Tonix Pharmaceuticals Holding Corp. (US:TNXP) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 15, 2025 disclosing 10,525 shares of Tonix Pharmaceuticals Holding Corp.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-11-14 2025-09-30 13F TONIX PHARMACEUTICALS HLDG C COM NEW 890260839 0 -10,525 -100.00 0 -100.00
2025-08-15 2025-06-30 13F TONIX PHARMACEUTICALS HLDG C COM NEW 890260839 10,525 -4,475 -29.83 379 41.04 0.0031
2025-05-13 2025-03-31 13F TONIX PHARMACEUTICALS HLDG C COM NEW 890260839 15,000 15,000 268 0.0025
2022-08-15 2022-06-30 13F TONIX PHARMACEUTICALS HLDG C COM 890260706 0 -20,000 -100.00 0 -100.00
2022-05-13 2022-03-31 13F TONIX PHARMACEUTICALS HLDG C COM 890260706 20,000 0 0.00 5 -28.57 0.0001
2022-02-11 2021-12-31 13F TONIX PHARMACEUTICALS HLDG C COM 890260706 20,000 0 0.00 7 -41.67 0.0001
2021-11-12 2021-09-30 13F TONIX PHARMACEUTICALS HLDG C COM 890260706 20,000 0 0.00 12 -45.45 0.0002
2021-08-11 2021-06-30 13F TONIX PHARMACEUTICALS HLDG C COM 890260706 20,000 0 0.00 22 -15.38 0.0004
2021-05-14 2021-03-31 13F TONIX PHARMACEUTICALS HLDG C COM 890260706 20,000 0 0.00 26 85.71 0.0005
2021-02-09 2020-12-31 13F TONIX PHARMACEUTICALS HLDG C COM 890260706 20,000 0 0.00 14 -17.65 0.0003
2020-11-13 2020-09-30 13F TONIX PHARMACEUTICALS HLDG C COM 890260706 20,000 10,000 100.00 17 183.33 0.0004
2020-08-13 2020-06-30 13F TONIX PHARMACEUTICALS HLDG C COM 890260706 10,000 10,000 6 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.